gabapentin enacarbil

Gabapentin enacarbil is a prodrug of gabapentin, classified as an anticonvulsant and analgesic in the gabapentinoid class. It was developed to improve oral bioavailability compared to gabapentin and is formulated as an extended-release tablet. After absorption, it is converted into active gabapentin by first-pass hydrolysis. Gabapentin enacarbil is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN) in adults. Its mechanism of action is not fully understood but likely involves modulation of voltage-dependent calcium channel subunits (especially alpha2-delta), leading to decreased release of excitatory neurotransmitters and activation of spinal alpha2-adrenergic receptors[1][4][5][6]. The drug provides more predictable pharmacokinetics than immediate-release gabapentin, with dose-proportional systemic exposure and reduced dosing frequency due to its extended-release formulation.

Brand names

HorizantRegnite

Other names

gabapentin enacarbil